List of Excipients in Branded Drug AMPYRA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Merz Pharmaceuticals LLC	AMPYRA	dalfampridine	0259-5010	CELLULOSE, MICROCRYSTALLINE
Merz Pharmaceuticals LLC	AMPYRA	dalfampridine	0259-5010	HYPROMELLOSE
Merz Pharmaceuticals LLC	AMPYRA	dalfampridine	0259-5010	MAGNESIUM STEARATE
Merz Pharmaceuticals LLC	AMPYRA	dalfampridine	0259-5010	POLYETHYLENE GLYCOL

AMPYRA Excipient Strategy and Commercial Opportunities in Dalfampridine Extended-Release Tablets

Last updated: September 2, 2026

AMPYRA is a 10 mg extended-release dalfampridine tablet approved in the United States to improve walking in adults with multiple sclerosis. Its commercial value has shifted from brand exclusivity to generic manufacturing, formulation engineering, supply reliability, and differentiated modified-release products. The core opportunity is a robust once-every-12-hours matrix tablet that maintains bioequivalence without increasing peak exposure, dose dumping, or seizure risk.

What is AMPYRA and how is its formulation designed?

AMPYRA contains dalfampridine, also known as 4-aminopyridine, in a 10 mg extended-release tablet. The labeled dose is one tablet every 12 hours, with a maximum of two tablets per day. The product is not intended to be split, crushed, chewed, or dissolved because those actions can alter release and increase exposure.[1]

Attribute	AMPYRA specification
Active ingredient	Dalfampridine
Strength	10 mg
Dosage form	Extended-release film-coated tablet
Administration	One tablet every 12 hours
Indication	Improvement of walking in adults with multiple sclerosis
Key safety limitation	Contraindicated in patients with a history of seizures and moderate or severe renal impairment
Renal restriction	Contraindicated when creatinine clearance is 50 mL/min or less
FDA approval	2010
Original sponsor	Acorda Therapeutics

Dalfampridine has a narrow margin between therapeutic exposure and toxicity. Seizures are the principal dose-related safety concern. Renal clearance is commercially important because reduced kidney function can increase systemic exposure. These factors limit the practical value of simple strength extensions or aggressive release acceleration.[1]

What excipients are used in AMPYRA tablets?

The AMPYRA label identifies a conventional tablet core and film-coating system. The inactive ingredients include microcrystalline cellulose, colloidal silicon dioxide, magnesium stearate, sodium lauryl sulfate, hypromellose, polyethylene glycol, and titanium dioxide.[1]

Excipient	Likely formulation function	Commercial relevance
Microcrystalline cellulose	Diluent, dry-binder, compression aid	Supports tablet strength and content uniformity
Colloidal silicon dioxide	Glidant, flow-control agent	Helps manage low-dose drug distribution and powder flow
Magnesium stearate	Lubricant	Reduces ejection force; excessive use can slow wetting and dissolution
Sodium lauryl sulfate	Wetting or dissolution aid	Can improve reproducibility for a poorly wetting drug substance
Hypromellose	Film coating and possible release-control polymer	Supports coating integrity and tablet handling
Polyethylene glycol	Plasticizer in film coating	Improves coating flexibility and reduces cracking
Titanium dioxide	Opacifier and pigment	Provides coating appearance and light protection

The label does not establish that any individual excipient is responsible for AMPYRA’s clinical effect. The commercial significance lies in the combined process and performance of the tablet: drug distribution, compaction, coating, polymer hydration, dissolution, and stability.

Which excipient attributes matter most for generic dalfampridine?

The highest-value attributes are those that control dose uniformity and release consistency.

Content uniformity

Each tablet contains only 10 mg of active ingredient. The formulation therefore requires tight control of:

• Dalfampridine particle-size distribution
• API segregation during blending and transfer
• Blend uniformity
• Granule or powder flow
• Compression-force variability
• Tablet weight and hardness

Microcrystalline cellulose and colloidal silicon dioxide can support flow and compaction, but excipient grade changes can affect segregation, bulk density, and tablet tensile strength. A supplier change that appears minor on paper can alter dissolution or content-uniformity performance.

Extended-release dissolution

The formulation must release dalfampridine over approximately 12 hours without an early burst. A generic manufacturer must control:

• Polymer viscosity and substitution characteristics
• Tablet porosity
• Compression force
• Lubrication time
• Coating weight gain
• Tablet dimensions
• Dissolution across multiple pH conditions
• Agitation sensitivity
• Alcohol interaction, where relevant to the product design

For this product, a faster dissolution profile is not necessarily commercially attractive. Increased early exposure can create a safety problem even if total exposure remains similar.

Excipient compatibility

Dalfampridine is a small, water-soluble ionizable molecule. Excipient selection can influence wetting, microenvironmental pH, diffusion through the hydrated matrix, and release reproducibility. Sodium lauryl sulfate may improve wetting, but it also requires control because surfactant level and distribution can affect dissolution.

Magnesium stearate is another critical process variable. Over-lubrication can reduce tablet wettability and slow or distort drug release. The risk is greater when a manufacturer changes blender type, lubricant addition time, or compression conditions.

What formulation patents protected AMPYRA?

AMPYRA’s historic patent estate focused on extended-release dalfampridine formulations and related methods rather than on a broad composition-of-matter monopoly over dalfampridine itself. Acorda’s patents were central to the company’s efforts to delay generic entry and protect its modified-release product.[2][3]

Patent category	Commercial purpose
Extended-release composition patents	Protect a controlled-release dalfampridine tablet
Manufacturing and formulation claims	Protect matrix composition, processing, or release characteristics
Method-of-use claims	Cover use of dalfampridine to improve walking in multiple sclerosis
Regulatory listings	Support listed-patent certifications in abbreviated new drug applications

The principal legal issue was whether generic products would infringe valid AMPYRA formulation patents and whether those patents were enforceable. Acorda litigated against prospective generic entrants, including Roxane Laboratories and other abbreviated new drug application sponsors.[2][3]

The commercial protection period has ended for practical purposes. FDA-approved generic dalfampridine extended-release products are available, and the market is no longer dependent on the AMPYRA brand for access to the formulation category.[4]

When did AMPYRA lose exclusivity and generic entry begin?

AMPYRA received FDA approval in 2010. Generic entry followed patent litigation and settlement activity, with FDA-approved dalfampridine extended-release products entering the U.S. market in 2018.[4][5]

Milestone	Date or period
FDA approval of AMPYRA	2010
Early patent litigation against ANDA applicants	2011 onward
First major generic litigation decisions	2014-2016
Generic market entry	2018
Current market structure	Brand plus multiple generic suppliers

The Hatch-Waxman pathway made Paragraph IV certification strategically important. Generic applicants challenged listed patents by asserting invalidity, unenforceability, or non-infringement. Patent litigation created a delay between FDA approval of generic products and commercial launch.

The relevant business lesson is that the product’s primary barrier was not the excipient cost. It was the ability to reproduce the extended-release performance while managing patent risk and FDA bioequivalence requirements.

What is the Orange Book status of AMPYRA?

The FDA Orange Book historically listed AMPYRA-related patents, including patents covering extended-release formulations and use. Current commercial diligence should distinguish between:

1. Historical patents that shaped generic entry.
2. Patents that were listed during ANDA review.
3. Patents that remain enforceable for a particular legal purpose.
4. Regulatory exclusivity that has already expired.
5. Patent claims that may be irrelevant to a newly designed product.

The presence of an Orange Book patent does not by itself establish that the patent blocks every modified-release dalfampridine product. Claim scope, expiration, litigation outcomes, settlement terms, and the specific formulation must be assessed together.

Which companies challenged AMPYRA patents?

Acorda faced ANDA-based patent challenges from generic manufacturers, including Roxane Laboratories and other applicants. The litigation concerned AMPYRA patents directed to extended-release dalfampridine products.[2][3]

The competitive landscape now includes multiple generic manufacturers. FDA records identify approved dalfampridine extended-release tablets from companies including Mylan, Teva, and other applicants over time, although product availability can vary by wholesaler, payer, and manufacturing status.[4]

The main competitive variables are:

• Approved product status
• Commercial supply capacity
• Wholesale acquisition cost
• Payer formulary access
• Ability to maintain dissolution similarity
• Manufacturing-site reliability
• Recalls and inspection history
• Regional distribution coverage

What excipient strategies create commercial opportunities?

1. Generic substitution with low formulation risk

The lowest-risk strategy is a direct generic equivalent using widely accepted excipients and a release-control process that matches the reference product. Opportunities exist for manufacturers that can lower cost without changing:

• Tablet dimensions
• Release profile
• Stability profile
• Food-effect behavior
• Dose uniformity
• Film-coating performance

The most defensible advantage may come from process capability rather than a novel excipient.

2. Excipient-grade optimization

A manufacturer can create value through tighter control of excipient attributes, including:

• Microcrystalline cellulose particle size and moisture
• Hypromellose viscosity grade
• Silicon dioxide surface area
• Magnesium stearate specific surface area
• Sodium lauryl sulfate purity and particle distribution

This approach can improve batch-to-batch reproducibility, reduce dissolution failures, and simplify scale-up. It is particularly relevant for contract development and manufacturing organizations supplying multiple markets.

3. Alternative release-control systems

A new matrix system could support a 505(b)(2) or other regulatory strategy if it provides a meaningful clinical or pharmaceutical advantage. Potential platforms include:

• Hydrophilic polymer matrices
• Insoluble or semi-permeable matrix systems
• Multiparticulate capsules
• Osmotic delivery systems
• Coated pellets or minitablets
• Abuse-deterrent or dose-dumping-resistant designs

The regulatory burden rises sharply if the product changes peak concentration, time to peak, food effect, or renal exposure. A formulation that produces a clinically different exposure profile may require more than routine ANDA evidence.

4. Patient-centered dosage forms

Potential lifecycle concepts include:

• Easier-to-swallow tablets
• Smaller tablets with equivalent release
• Sprinkle-compatible multiparticulates
• Packaging that reduces dosing errors
• Improved tablet identification
• Formulations with reduced sensitivity to crushing or chewing

These opportunities are constrained by the need to preserve controlled release. A sprinkle product or orally disintegrating system would require strong evidence that the drug is not released too rapidly.

5. Excipient replacement

Excipient replacement can support regional registration, supply continuity, or patient preference claims. Potential targets include:

• Replacing sodium lauryl sulfate where local labeling or tolerability concerns matter
• Developing lactose-free or sugar-free variants
• Using alternative coating pigments
• Reducing reliance on a single hypromellose supplier
• Establishing dual-source lubricant and glidant systems

A replacement is commercially useful only if it maintains dissolution, stability, and bioequivalence. “Clean-label” positioning has limited value in a prescription MS product unless it solves a specific payer, patient, or supply problem.

What manufacturing barriers protect the commercial position?

The most important barriers are technical and regulatory.

Low-dose formulation control

The 10 mg strength increases sensitivity to blend uniformity and segregation. Continuous manufacturing, engineered API particle size, or ordered-mixing approaches may reduce variability, but each process change requires validation.

Release-profile equivalence

A manufacturer cannot rely only on average dissolution similarity. The product must perform across media, apparatus, agitation conditions, storage periods, and relevant tablet strengths or manufacturing lots.

Renal and seizure-risk profile

The safety margin limits formulation experimentation. A product with a higher early release rate may face clinical and regulatory concerns even if the total amount released is unchanged.

Scale-up and supplier changes

Changes in hypromellose grade, lubricant concentration, coating equipment, or tablet press settings can create a material dissolution shift. This gives experienced manufacturers an advantage over low-cost entrants with limited modified-release capability.

How strong is the current AMPYRA patent estate?

The original patent estate was commercially meaningful because it delayed generic commercialization and supported litigation leverage. Its current value is materially lower because generic products are approved and the main exclusivity period has passed.

Estate element	Current commercial assessment
Dalfampridine molecule	Weak as a standalone exclusivity platform
Original AMPYRA formulation	Historically strong, now largely eroded
New release-control technology	Potentially valuable if technically distinct and clinically meaningful
Method-of-use claims	Limited value against approved generic substitution where the same indication is labeled
Manufacturing know-how	Moderate value, especially for consistent dissolution and scale-up
Excipient supplier relationships	Operational value rather than classic exclusivity

The strongest remaining opportunity is a new product with differentiated delivery, improved adherence, or a measurable safety or usability benefit. A minor excipient substitution is unlikely to produce durable exclusivity by itself.

What licensing deals and commercial partnerships are relevant?

Acorda’s commercial strategy involved partnerships and later corporate ownership changes rather than a durable excipient-specific licensing platform. Merz acquired Acorda in 2020, including AMPYRA-related assets and commercial operations.[6]

For new entrants, the more relevant transaction structures are:

• Licensing a modified-release platform
• Regional rights for generic dalfampridine
• Contract manufacturing and supply agreements
• Co-development of multiparticulate or abuse-resistant products
• Excipient supply agreements with dual-source provisions
• Private-label distribution through specialty pharmacies

The commercial target is a product with lower cost of goods, reliable supply, or differentiated access rather than another undifferentiated tablet.

What generic launch scenarios exist for dalfampridine?

Base case: price-driven generic erosion

Multiple suppliers compete on price, payer contracts, and availability. Brand demand contracts unless AMPYRA retains a specific reimbursement or patient-support advantage.

Supply-constrained generic market

Manufacturing interruptions, API shortages, or quality problems can temporarily improve margins for suppliers with validated backup capacity.

Differentiated modified-release product

A 505(b)(2) product could compete on adherence, swallowing, dose-dumping resistance, or patient handling. It would require a clear clinical or pharmaceutical rationale.

Regional market opportunity

Markets outside the United States may have less mature competition or different registration requirements. Opportunities depend on local approval status, patent position, reference-product availability, and reimbursement for MS therapies.

Key Takeaways

• AMPYRA is a 10 mg extended-release dalfampridine tablet taken every 12 hours.
• The core inactive ingredients include microcrystalline cellulose, colloidal silicon dioxide, magnesium stearate, sodium lauryl sulfate, hypromellose, polyethylene glycol, and titanium dioxide.[1]
• Commercial performance depends on dissolution control, content uniformity, and protection against dose dumping.
• The original AMPYRA patent strategy delayed generic entry but no longer provides broad market exclusivity.
• The strongest generic opportunities are process optimization, reliable supply, competitive pricing, and excipient-grade control.
• New products need a meaningful release, adherence, safety, or administration advantage to justify a differentiated regulatory pathway.
• Renal impairment and seizure risk materially restrict aggressive formulation changes.
• Excipient innovation alone is unlikely to support durable exclusivity without a distinct product or clinical benefit.

FAQs About AMPYRA Excipients and Commercial Strategy

Can AMPYRA be reformulated with different excipients?

Yes, but a generic manufacturer must demonstrate that the changes do not materially affect pharmaceutical performance, bioequivalence, stability, or labeling requirements.

Is dalfampridine an extended-release drug with a narrow therapeutic index?

Dalfampridine has clinically important dose-related seizure risk and exposure sensitivity, particularly in renal impairment. These characteristics make release-rate control central to product development.

Does AMPYRA have a composition-of-matter patent on dalfampridine?

The principal commercial protection for AMPYRA was associated with its extended-release product and use, not a broad modern composition-of-matter monopoly over the underlying small molecule.

Could a multiparticulate dalfampridine product receive separate market protection?

Potentially. A multiparticulate product could support patent claims and a differentiated regulatory strategy if it provides a distinct release profile, administration benefit, or clinically relevant performance advantage.

Are excipients a significant cost component of generic AMPYRA?

Usually no. API cost, manufacturing yield, quality testing, regulatory compliance, packaging, distribution, and payer pricing generally have greater commercial impact than the unit cost of common tablet excipients.

References

1. U.S. Food and Drug Administration. (2023). AMPYRA (dalfampridine) extended-release tablets: Prescribing information.
2. U.S. Court of Appeals for the Federal Circuit. (2014). Acorda Therapeutics, Inc. v. Roxane Laboratories, Inc., 752 F.3d 1345.
3. U.S. District Court for the District of Delaware. (2016). Acorda Therapeutics, Inc. v. Roxane Laboratories, Inc., patent litigation concerning AMPYRA extended-release dalfampridine tablets.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. U.S. Food and Drug Administration. (2018). FDA approves first generic versions of Ampyra to treat multiple sclerosis.
6. Merz Pharma GmbH & Co. KGaA. (2020). Merz completes acquisition of Acorda Therapeutics.